Treatment of bipolar depression
DOI:
https://doi.org/10.25118/2763-9037.2011.v1.877Keywords:
BD, bipolar disorder, Ayahuasca; Depression; Psilocybin, treatment, medication, antipsychotics, antidepressants, mood stabilizersAbstract
Although manic states are the defining conditions for the diagnosis of bipolar disorder, depressive states are the most common symptomatic conditions in patients’ lives and are responsible for most of the disability and suffering experienced by patients with bipolar disorder (Goodwin & Jamison, 2007). In a 10-year follow-up study, patients with bipolar I disorder were depressed 31% of the time, more than they were manic (9%) or mixed (9%) (Judd et al., 2003a). Patients with bipolar II disorder were depressed 50.3% of the time, much more than they were hypomanic (1.3%) (Judd et al., 2003b). Approximately 50% of patients with bipolar disorder have a depressive episode as the first manifestation of the illness, and depressive episodes can be chronic in 20% of patients and be more refractory to treatment than manic or hypomanic episodes (Yatham et al., 2005). Bipolar depression, whether the depressive episode or the subsyndromal symptoms, also contributes to a large part of the loss of functionality and quality of life of patients with bipolar disorder (Goodwin & Jamison, 2007).
Downloads
Metrics
References
Goodwin FK, Jamison KR. Manic-Depressive Illness: Bipolar Disorder and Recurrent Depression. 2nd ed. New York: Oxford University Press; 2007.
Judd LL, Akiskal HS, Schetter PJ, et al. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry 2003; 59: 530-537. DOI: https://doi.org/10.1001/archpsyc.59.6.530
Judd LL, Akiskal HS, Schettler PJ, et al. A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder. Arch Gen Psychiatry 2003; 60: 261-269. DOI: https://doi.org/10.1001/archpsyc.60.3.261
Yatham LN, Kennedy SH, O’Donovan C, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies. Bipolar Disord 2005; Suppl 3:5-69. DOI: https://doi.org/10.1111/j.1399-5618.2005.00219.x
Ghaemi SN. Why antidepressants are not antidepressants: STEP-BD, STAR*D, and the return of neurotic depression. Bipolar
Disord 2008; 10: 957-968. DOI: https://doi.org/10.1111/j.1399-5618.2008.00639.x
Perlis RH, Brown E, Baker RW, et al. Clinical features of bipolar depression versus major depressive disorder in large multicenter
trials. Am J Psychiatry 2006; 163: 225-231. DOI: https://doi.org/10.1176/appi.ajp.163.2.225
Abreu LN, Lafer B, Baca-Garcia E, Oquendo MA. Suicidal ideation and suicide attempts in bipolar disorder type I: an update for the clinician. Rev Bras Psiquiatr 2009; 31: 271-280. DOI: https://doi.org/10.1590/S1516-44462009005000003
Malhi S, Adams D, Berk M. Medicating mood with maintenance in mind: bipolar depression pharmacotherapy. Bipolar Disord 2009; Suppl 2: 55-76. DOI: https://doi.org/10.1111/j.1399-5618.2009.00711.x
Yatham LN, Kennedy SH, Schaffer A, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International
Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009. Bipolar Disord 2009; 11: 225-255. DOI: https://doi.org/10.1111/j.1399-5618.2009.00672.x
Zornberg GL, Pope HG Jr. Treatment of depression in bipolar disorder: new directions for research. J Clin Psychopharmacol
; 13: 397-408.
Frye MA, Ketter TA, Kimbrell TA, et al. A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory
mood disorders. J Clin Psychiatry 2000; 20: 607-614. DOI: https://doi.org/10.1097/00004714-200012000-00004
Calabrese JR, Huffman RF, White RL, et al. Lamotrigine in the acute treatment of bipolar depression: results of fivedouble-blind, placebo-controlled clinical trials. Bipolar Disord 2008; 10: 323-33. DOI: https://doi.org/10.1111/j.1399-5618.2007.00500.x
Geddes JR, Calabrese JR, Goodwin GM. Lamotrigine for treatment of bipolar depression: independent meta-analysis and
meta-regression of individual patient data from five randomised trials. Br J Psychiatry 2009; 194: 4-9. DOI: https://doi.org/10.1192/bjp.bp.107.048504
van der Loos ML, Mulder P, Hartong EG, et al. Efficacy and safety of two treatment algorithms in bipolar depression consisting
of a combination of lithium, lamotrigine or placebo and paroxetine. Acta Psychiatr Scand 2010; 122: 246-54. DOI: https://doi.org/10.1111/j.1600-0447.2009.01537.x
Ghaemi SN, Gilmer WS, Goldberg JF, et al. Divalproex in the treatment of acute bipolar depression: a preliminary double-
-blind, randomized, placebo-controlled pilot study. J Clin Psychiatry 2007; 68: 1840-1844. DOI: https://doi.org/10.4088/JCP.v68n1203
Muzina DJ, Gao K, Kemp DE, et al. Acute efficacy of divalproex sodium versus placebo in mood stabilizer-naïve bipolar
I or II depression: a double-blind, randomized, placebo-controlled trial. J Clin Psychiatry 2010; 24: Epub ahead of print.
Small JG. Anticonvulsants in affective disorders. Psychopharmacol Bull 1990; 26: 25-36.
Calabrese JR, Keck PE, Macfadden W, et al. A randomized double blind placebo controlled trial of quetiapine in the treatment
of bipolar I and II depression. Am J Psychiatry 2005; 162: 1351-1360. DOI: https://doi.org/10.1176/appi.ajp.162.7.1351
Thase ME, Macfadden W, Weisler RH, et al. Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-
-blind, placebo-controlled study (the BOLDER II study). J Clin Psychopharmacol 2006; 26: 600-609. DOI: https://doi.org/10.1097/01.jcp.0000248603.76231.b7
Tohen M, Vieta E, Calabrese J, et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry 2003; 60: 1079-1088. DOI: https://doi.org/10.1001/archpsyc.60.11.1079
Tamayo JM, Zarate CA Jr, Vieta E, et al. Level of response and safety of pharmacological monotherapy in the treatment of acute bipolar I disorder phases: a systematic review and meta-analysis. Int J Neuropsychopharmacol 2010; 18: 813-832. DOI: https://doi.org/10.1017/S1461145709991246
Tamada RS, Issler CK, Amaral JA, Sachs GS, Lafer B. Treatmentemer gent affective switch: a controlled study. Bipolar Disord 2004; 6: 333-7. DOI: https://doi.org/10.1111/j.1399-5618.2004.00124.x
Baldessarini RJ, Vieta E, Calabrese JR, et al. Bipolar depression: overview and commentary. Harv Rev Psychiatry 2010; 18: DOI: https://doi.org/10.3109/10673221003747955
-157.
Post RM, Altshuler LL, Leverich GS, et al. Mood switch in bipolar depression: comparison of adjunctive venlafaxine, bupropionand sertraline. Br J Psychiatry 2006; 189: 124-131. DOI: https://doi.org/10.1192/bjp.bp.105.013045
Nemeroff CB, Evans DL, Gyulai L, et al. Double-blind, placebo-controlled comparisons of imipramine and paroxetine in the treatment of bipolar depression. Am J Psychiatry 2001; 158: 906-912. DOI: https://doi.org/10.1176/appi.ajp.158.987.906
Macedo-Soares MB, Moreno RA, Rigonatti SP, Lafer B. Efficacy of electroconvulsive therapy in treatment-resistant bipolar
disorder: a case series. J ECT 2005; 21: 31-4. DOI: https://doi.org/10.1097/01.yct.0000148621.88104.f1
Nery FG, Monkul ES, Hatch JP, Fonseca M, Zunta-Soares GB, Frey BN, Bowden CL, Soares JC. Celecoxib as an adjunct in the treatment of depressive and mixed episodes of bipolar disorder: a double-blind, randomized, placebo-controlled study. Hum Psychopharmacol 2008; 23: 87-94. DOI: https://doi.org/10.1002/hup.912
Frye MA, Grunze H, Suppes T, et al. A placebo-controlled study of adjunctive modafinil in the treatment of bipolar depression.
Am J Psychiatry 2007; 164: 1242-1249.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2011 Beny Lafer, Fabiano G. Nery
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Debates em Psiquiatria allows the author (s) to keep their copyrights unrestricted. Allows the author (s) to retain their publication rights without restriction. Authors should ensure that the article is an original work without fabrication, fraud or plagiarism; does not infringe any copyright or right of ownership of any third party. Authors should also ensure that each one complies with the authorship requirements as recommended by the ICMJE and understand that if the article or part of it is flawed or fraudulent, each author shares responsibility.
Attribution-NonCommercial 4.0 International (CC BY-NC 4.0) - Debates em Psiquiatria is governed by the licencse CC-By-NC
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material
The licensor cannot revoke these freedoms as long as you follow the license terms. Under the following terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- NonCommercial — You may not use the material for commercial purposes.
No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
